Speaker Names
Andrew Musgrave Host
00:01
Welcome back to ASX Briefs, and joining me today is Dr James Garner, the Managing Director and CEO of Percheron Therapeutics, a clinical stage biotech company dedicated to developing innovative therapies for rare diseases. James, thanks for joining me today and welcome to the ASX Briefs podcast.
James Garner Guest
00:19
Thanks, Andrew, it's great to be here.
Andrew Musgrave Host
00:21
Okay, so for investors that may be unfamiliar with the company, can you just start by giving us an overview of a company and the name change as well?
James Garner Guest
00:29
Andrew, it's a pleasure. So, a couple of things to say about Percheron. First is that we're a rare diseases company, as you mentioned in your intro, and people sometimes say why rare diseases when you want to go after common diseases? But the reality is that these rarer diseases, diseases that are a bit less common than, say, diabetes or high blood pressure, high cholesterol they can be very, very attractive spaces, particularly for smaller companies. The economics of developing a drug there can be really favorable for companies like ours. So, it's a much more realistic and, frankly, in many ways an economically more favorable space than some of these sort of mass market type indications.
01:10
And specifically, our focus is on a disease called Duchenne muscular dystrophy, which is a genetic disease of children. Absolutely devastating disease leads to progressive muscle weakness and ultimately, life expectancy is in the mid-20s for patients with this disease. And, of course, we're a publicly listed company. We're listed on the Australian Securities Exchange, and we trade there under the ticker PER. And, as you mentioned, the company used to be called Antisense Therapeutics and we changed our name right at the beginning of this year the beginning of 2024, really to reflect the fact that the company has been through a lot of change. I think we've changed our strategy, changed most of our team, changed how we think about the development of this drug, and it just seemed a nice way to signal the fact that the company's been through this metamorphosis to investors. So, we're still getting used to being Percheron, but it's starting to feel like home.
Andrew Musgrave Host
02:08
Okay, and the company has recently completed recruitment for the phase 2b trial of avicursen in the non-ambulant boys with DMD, so can you share more about the trial's design and what we should expect in the upcoming data readout later this year?
James Garner Guest
02:24
Yeah, thanks, Andrew. The nice thing is this is a really solid clinical trial. It's what we call a randomized controlled trial. So that means all the patients in the trial are randomly allocated either to get our drug or to get a placebo, and they don't know which is which. And the advantage of this is it really eliminates most of the potential sources of bias in a clinical trial. So, for regulatory agencies like FDA or TGA here in Australia, this is considered the gold standard evidence. This is what they really want to see from companies like ours. So, we tick that box.
03:02
It's a double-blind randomized controlled trial. That, as I say, the gold standard for investigating new drugs. It's a well-powered study, and when we talk about power in clinical trials, we're really talking about has it got enough patients to show an effect. This trial has 48 patients, which is a very decent size in a disease like Duchenne. Obviously, some diseases like, say, type 2 diabetes, we sometimes see thousands of patients, but in a disease like this, this feels like a good sort of size.
03:31
It's pretty comparable to other drugs in development and we're using an endpoint, a measure of the drug's efficacy, called PUL2.0. And this is really a measure of how well these boys can use their arms. And you might say, why arms? But, as you noted, we're doing this study in non-ambulant boys, and that's actually in patients who have progressed far enough in the course of their disease that they have effectively become wheelchair-bound, and so we can't look at things like walking tests, stair climbing tests. We look at arm function. PUL2.0 is the gold standard measure of arm function. It stands for performance in the upper limb, and so that's how we're measuring the efficacy of this study, and so a really robust, well-designed, solid study, as you say, our first data readout coming up in December.
Andrew Musgrave Host
04:27
And the recent completion of the nine-month non-human primate toxicology study has shown a significant milestone. So, can you elaborate on the importance of these findings and how they align with the FDA's requirements for clinical trials in the US?
James Garner Guest
04:46
Yes, it's good to have this piece of work done, FDA. Well, in fact, all regulatory agencies require us to do a certain amount of safety testing, toxicology testing in animals, some of it before we can give the drug to humans and some of it before we can give the drug to humans in large numbers or for long periods of time, and those requirements differ a little bit between regulatory agencies. So, every country's regulatory agency has a very slightly different set of requirements, slightly different risk tolerance. Really. Now for us, FDA has required a nine-month study in monkeys.
05:21
This isn't a requirement for Europe, as it happens, but FDA is very clear that they wanted this study and it's not a requirement that's specific to our company. It's something that's there in FDA guidelines. It's something they require really as a fairly routine matter for drugs like this. But unfortunately, it inadvertently became a rate-limiting step in the development of our drug, just in the melee of drug development. It was something that happened a little bit later, perhaps in hindsight, than it should have, and so it at the moment makes it difficult for us to run clinical trials in the US. We hope that the study we've done should remove those barriers. Certainly, to our eye the data looks very innocuous, very consistent with previous work. There's really no surprises in there. Obviously, we have to go and have that conversation with FDA and we plan to do that in early 2025. But it's certainly not flashing any red lights on our dashboard, and we think that we can have a good, constructive discussion with FDA and hopefully open the door to not just clinical trials in the United States but eventually commercialization there.
Andrew Musgrave Host
06:39
And the company closed out Q2 of 2024 with a cash balance just shy of $12 million. So, can you discuss your strategy for maintaining resources to ensure the company keeps the momentum through these critical development stages?
James Garner Guest
06:53
It's always the challenge for small pre-revenue biotechs. Right Cash management is such an important focus. We actually just recently added a very, very well qualified chief financial officer to our team who's just brought an enormous sense of discipline and some really great forecasting rigor to this, so I think it's going to help enormously. We do run very lean as a business. As a very, very crude, historical average, we spend something like a million dollars a month in round terms. But the reality for biotech companies is that spend is very, very lumpy, particularly once you're doing clinical trials. You have some very, very expensive months, some very quiet months, some busy quarters, some quiet quarters, so it is lumpy.
07:44
And this is something that I think investors sometimes find challenging is they'll see a very cheap quarter and they'll think, oh well, that's how it's going to be, and then the next quarter it's quite expensive and they wonder what's changed and in reality, nothing's changed. It's just the cadence of the clinical trial. But we're getting very, very good at forecasting our expenditures. We have a very, very clear picture of how long this goes and, in addition to the approximately $12 million we had at 30th of June 2024, we have just received an R&D tax incentive rebate from the federal government to the tune of a little under $2.4 million. You get a little bit of interest from the bank and things like that along the way. So, we've got a little bit of money at our disposal. We certainly can't get carried away as a business, but we're in the fortunate position that we can focus as much as possible on the clinical trial work and not so much on the day-to-day financing anxieties.
Andrew Musgrave Host
08:44
And if we can just touch on the regulation side in a little bit more detail. So obviously the results are on the horizon. So how do you I think a lot of people would like to know how do you handle those discussions with the FDA and other regulators to progress those results and get a positive outcome?
James Garner Guest
09:00
Well with great care, is probably the short answer. Procedurally, these are quite complex and very highly structured discussions, so we don't just sort of rock up in the FDA's offices and say we'd like to chat about our drug. There's quite a lot of formality to these things. The good news is that we've got a team that's done this before quite a few of our team of firsthand experience of these kinds of consultations and we do work with some external consultants and advisors who are very, very experienced in this and who can help us do all the legwork that's required in advance. So, the good news is we're not doing any of this for the first time. Very, very broadly, we see sort of two directions that FDA can point us in here, and we plan to go to them in early calendar 2025, not just with that animal toxicology data that we just spoke about, but also with the first data from our clinical trial, and so we want to really show them a very, very solid package of data and say, look, here's how our drug is doing, here's the animal data you asked for, but here's also some human data and here's how it looks.
10:21
We think there's a couple of ways in the medium term that our consultations with FDA could go for. One is that we may be able to have a discussion with FDA about what they call accelerated approval. Now the current clinical trial we're doing is technically what we call a phase two clinical trial. Ordinarily, phase two is not mature enough to talk about a product approval. Technically there's three phases of clinical development, but in diseases like this, FDA will often show some flexibility and can approve drugs on the basis of less than a full phase three study. So, if our data looks good, we'd really like to have that discussion with them, because obviously that could potentially get the drug to patients much sooner and hopefully start providing benefit.
11:12
If we're not quite in that territory, then I think the discussion becomes well. What else does FDA need to see from us? What are the key concerns, key anxieties, key requirements they still have? And then we can go away and do whatever clinical work is necessary to fulfill those needs. But we would do so, obviously, with the benefit of having a really clear data readout in hand and having very clear and specific guidance from FDA. Data readout in hand and having very clear and specific guidance from FDA. So, we think they're all good outcomes in a way, but I think that's going to be, in some ways, the key question for us next year.
Andrew Musgrave Host
11:47
And the company has a strong collaboration history, including a longstanding partnership with Ionis Pharmaceuticals. So, can you tell us a bit more about these partnerships, how they've contributed to your current pipeline, and are there any other future plans for collaboration?
James Garner Guest
12:03
Yes, we're very mindful that few companies do everything well, especially in our line of work, especially in pharmaceuticals. Some companies are very, very good at the science. Some are very good at clinical development, some are very good commercial agents. Not many companies are great at everything. So, we've tried to observe a certain kind of modesty in our ambitions and tried to recognize what we can do well and what we're better off leaving to other people.
12:34
We recognize that in terms of the basic science, the discovery work, the creation of new molecules, Ionis has one of the most impressive track records in the industry. It has one of the most enviable technology platforms in the industry for this kind of drug. So, we're thrilled to be able to work with them. And although I think we've provided a lot of you know a lot of the work that's gone into the creation of our drugs, we have relied deeply on Ionis' expertise and on its technology and we've benefited enormously from that relationship. And if we'd had to recreate the wheel for ourselves, it would have taken many millions of dollars and many years extra. In the clinical piece and the work, we're doing now. We really like to own the strategy. So, we think it's very important as a company we own the thinking piece about how to develop our drug, but the executional part we outsourced extensively. So, we work with contract research organizations and contract manufacturing organizations to do all the hard work. Very expensive for us to build that infrastructure ourselves and very, very much more cost effective for that to be a variable cost.
13:59
And I think the next step in that is that when we think about commercialization of the product, we also think we're probably, in all humility, not the best people to do that. So, we are going to be looking to put the drug in the hands of one or more larger companies for commercialization and we want to have those discussions at the right time and in the right way. We've already been out there doing the legwork talking to potential partners, hearing their feedback, bringing them up to speed on the data we've seen so far. Probably our December data readout is going to be pivotal in this because, as I always say, nothing lubricates a partnering discussion, quite like new clinical data. But that's our ambition for the drugs. So, we're a company, I suppose, that tries to know our limits and we think that it behooves us to really try and do one thing really well, and we think the one thing we can do best is to own the clinical piece, knowing the development of our drug, and that's how we can add the most value.
Andrew Musgrave Host
14:56
Okay then, just to wrap things up, James. Obviously, FDA approval or FDA discussions are clearly the next cab off the rank. Are there any other milestones that shareholders can look forward to?
James Garner Guest
15:09
Andrew, I think you touch on a crucial one there. Obviously, the data itself is also a key thing, because that de-risks the drug in a way that almost nothing else can, and it's worth stressing. We are talking about data readouts plural rather than just one. Our first data readout is in December, but we'll be seeing more data in the middle of calendar 2025, and then more data again towards the back end of calendar 2025. So, one of the nice things about our trial design is it does give us a number of shots on goal, and so you know, we've got quite a material flow of clinical data coming through from this trial over, let's say, the next 15 months or so, so that alone makes it quite rich in terms of news flow.
16:01
As you say, our discussions with FDA are going to be really important, because I think that will provide us with clarity around the path forward for this drug. I think at the moment, you know we're sympathetic. This must be enormously frustrating sometimes for investors, but we can only really talk in terms of hypotheticals and scenarios at this stage, but as the data comes through, as our discussions with regulatory agencies progress, really that crystallizes and becomes a very, very clear path. And I think the other thing that I'd like to kind of I would hope that, let's say you know a year from now we'd be talking about is that we have succeeded in attracting some partner interest to the asset, not just because of the validation that provides for asset, not just because of the economic upside, but because this is a really promising drug and we think that having a really good partner alongside us will increase our chances of success. It'll help us expedite getting this drug to patients, and that's really what we want to achieve at the end of the day. So hopefully over the next 12, 15 months, something like that is how it's going to pan out for us.
Andrew Musgrave Host
17:14
Okay, James. Well, thanks for your time today. It's been great to get an update on the company and we look forward to further updates in the upcoming months.
James Garner Guest
17:21
Thanks so much, Andrew, it's been great to talk.
Andrew Musgrave Host
17:25
That concludes this episode of ASX Briefs. Don't forget to subscribe and we look forward to catching you on our next episode.